Nature Communications (Sep 2018)
The prognostic effects of somatic mutations in ER-positive breast cancer
- Obi L. Griffith,
- Nicholas C. Spies,
- Meenakshi Anurag,
- Malachi Griffith,
- Jingqin Luo,
- Dongsheng Tu,
- Belinda Yeo,
- Jason Kunisaki,
- Christopher A Miller,
- Kilannin Krysiak,
- Jasreet Hundal,
- Benjamin J Ainscough,
- Zachary L. Skidmore,
- Katie Campbell,
- Runjun Kumar,
- Catrina Fronick,
- Lisa Cook,
- Jacqueline E. Snider,
- Sherri Davies,
- Shyam M. Kavuri,
- Eric C. Chang,
- Vincent Magrini,
- David E. Larson,
- Robert S Fulton,
- Shuzhen Liu,
- Samuel Leung,
- David Voduc,
- Ron Bose,
- Mitch Dowsett,
- Richard K. Wilson,
- Torsten O. Nielsen,
- Elaine R Mardis,
- Matthew J. Ellis
Affiliations
- Obi L. Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Nicholas C. Spies
- McDonnell Genome Institute, Washington University School of Medicine
- Meenakshi Anurag
- Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine
- Malachi Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Jingqin Luo
- Siteman Cancer Center, Washington University School of Medicine
- Dongsheng Tu
- Genetic Pathology Evaluation Centre, University of British Columbia
- Belinda Yeo
- Institute of Cancer Research
- Jason Kunisaki
- McDonnell Genome Institute, Washington University School of Medicine
- Christopher A Miller
- McDonnell Genome Institute, Washington University School of Medicine
- Kilannin Krysiak
- McDonnell Genome Institute, Washington University School of Medicine
- Jasreet Hundal
- McDonnell Genome Institute, Washington University School of Medicine
- Benjamin J Ainscough
- McDonnell Genome Institute, Washington University School of Medicine
- Zachary L. Skidmore
- McDonnell Genome Institute, Washington University School of Medicine
- Katie Campbell
- McDonnell Genome Institute, Washington University School of Medicine
- Runjun Kumar
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Catrina Fronick
- McDonnell Genome Institute, Washington University School of Medicine
- Lisa Cook
- McDonnell Genome Institute, Washington University School of Medicine
- Jacqueline E. Snider
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Sherri Davies
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Shyam M. Kavuri
- Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine
- Eric C. Chang
- Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine
- Vincent Magrini
- McDonnell Genome Institute, Washington University School of Medicine
- David E. Larson
- McDonnell Genome Institute, Washington University School of Medicine
- Robert S Fulton
- McDonnell Genome Institute, Washington University School of Medicine
- Shuzhen Liu
- Genetic Pathology Evaluation Centre, University of British Columbia
- Samuel Leung
- Genetic Pathology Evaluation Centre, University of British Columbia
- David Voduc
- Genetic Pathology Evaluation Centre, University of British Columbia
- Ron Bose
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Mitch Dowsett
- Institute of Cancer Research
- Richard K. Wilson
- McDonnell Genome Institute, Washington University School of Medicine
- Torsten O. Nielsen
- Genetic Pathology Evaluation Centre, University of British Columbia
- Elaine R Mardis
- McDonnell Genome Institute, Washington University School of Medicine
- Matthew J. Ellis
- Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-05914-x
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Unravelling the link between somatic mutation and prognosis in estrogen positive (ER+) breast cancer requires the use of long-term follow-up data. Here, combining archival formalin-fixed paraffin embedded tissue and targeted sequencing in three cohorts of ER+ breast cancer, the authors find associations with clinical outcome for NF1 frame-shift nonsense mutations, PIK3R1 mutation, and DDR1 mutations.
